Health awareness

Triple-negative breast cancer: risks, signs and symptoms, and diagnosis

Learn about this aggressive type of breast cancer, including risk factors, signs and symptoms

October 12, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Breast cancer is the most commonly diagnosed cancer in the world. There are many different types and subtypes of breast cancer that are defined by where in the breast they begin, how much they have grown or spread and how they behave. One of the more aggressive types is triple-negative breast cancer (TNBC).

What’s triple-negative breast cancer?

The tumors of patients with breast cancer may be tested for three receptors, or proteins, that make cancer grow. If the tumor tests negative for estrogen and progesterone receptors and does not over express HER2, then that patient is diagnosed with TNBC.

Worldwide, there were more than 2.3 million patients diagnosed with breast cancer in 2020:

~10-15%

of people with breast cancer are diagnosed with TNBC

TNBC characteristically has a high recurrence rate within the first five years after diagnosis.

Who’s at risk for triple-negative breast cancer?

Primary risk factors for TNBC include:

  • Sex: People assigned female at birth are at higher risk for TNBC compared to people assigned male at birth.
  • Race /ethnicity: Non-Hispanic Black women are nearly two times as likely to have TNBC as non-Hispanic white women.
  • Age: TNBC is more common in women younger than 40.
  • Genetic mutations: Mutations in genes such as BRCA1 and BRCA2 are strongly associated with TNBC.

What are the signs and symptoms of breast cancer?

TNBC can have the same signs and symptoms as other common types of breast cancer.

Most breast cancers are detected before any symptoms appear through regular breast cancer screenings. The signs and symptoms of breast cancer differ from person to person, and some will never show symptoms.

However, some signs of breast cancer to watch out for include:

  • Swelling of all or part of a breast
  • Skin dimpling
  • Breast or nipple pain
  • Nipple retraction
  • Nipple or breast skin that’s red, dry, flaking or thickened
  • Nipple discharge
  • Swollen lymph nodes, under the arm or near the collar bone

How is triple-negative breast cancer diagnosed?

If you’re experiencing symptoms, speak with your doctor, especially if you have a higher risk of having TNBC. Some screening tests include:

  • Mammogram: An X-ray of the breast that allows doctors to look for changes in breast tissue. Mammograms can often find breast cancer early when it’s easiest to treat.
  • Magnetic resonance imaging (MRI): An MRI uses radio waves and strong magnets to make detailed pictures of the inside of the breast. Doctors use MRIs along with mammograms to screen people who are considered at high risk for breast cancer.
  • Ultrasound: An ultrasound uses sound waves and their echoes to make computer pictures of the inside of the breast. While not typically used as a routine screening test for breast cancer, an ultrasound can be useful for looking at some breast changes such as lumps – especially when they can be felt but not seen on a mammogram.
  • Biopsy: After a breast cancer diagnosis is made with a biopsy, a health care provider may determine whether a patient has TNBC with an assessment of cells from that biopsy, which are checked for estrogen, progesterone and HER2 receptors, to determine the cancer subtype.

How is triple-negative breast cancer staged?

Doctors use five stages to classify triple-negative breast cancer and inform next steps in your care plan:

Stage 0

Cancers diagnosed at stage 0 are confined to the milk ducts or lobules of the breast.


Stage 1

Cancers diagnosed at stage 1 are small, localized and have not spread beyond one nearby lymph node. Stage 1 TNBC is still considered early stage, so 91% of people diagnosed with this stage of cancer are alive five years after their diagnosis. Stage 1 cancer can be classified as either stage 1A or stage 1B dependent on the size of the tumor and whether there is evidence of cancer on the nearby lymph nodes.


Stage 2

Stage 2 TNBC may have spread regionally (beyond the initial site), but not beyond the lymph nodes in the underarm area. Stage 2 cancer can be classified as either stage 2A or stage 2B dependent on the size of the tumor and whether the breast cancer has spread to the lymph nodes. For patients whose cancer has spread to regional lymph nodes, 66% of people diagnosed are still alive five years after their diagnosis.


Stage 3

Stage 3 TNBC has extended beyond the immediate region of the tumor and may have invaded nearby lymph nodes and muscles but has not spread to distant organs. At this stage, TNBC can be classified as stage 3A, 3B or 3C, depending on the size of the tumor and how far it has spread. Stage 3 TNBC is considered to have spread regionally, and 66% of patients who are diagnosed at this stage are still alive five years after diagnosis.


Stage 4

Stage 4 TNBC, also known as metastatic breast cancer, has spread distantly to other areas or organs of the body, such as the brain, bones, lung or liver. This stage is not curable but is usually treatable, and current advances in research and medical technology mean that more people are living longer by managing the disease as a chronic illness. Twelve percent of patients diagnosed at this stage survive five years post-diagnosis.


Being diagnosed with TNBC can be scary. By speaking with your care team, you can better understand your options and the best path forward.

Innovation

Uniting research and manufacturing to help patients faster

The opening of our updated site in Ireland will increase collaboration and speed to market

October 5, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Great science requires collaboration. At MSD, scientists and engineers from across the company work together to achieve our purpose of using the power of leading-edge science to save and improve lives.

And at our new state-of-the-art site in Dunboyne, Ireland, we’re bringing together our research and manufacturing teams for the first time to support stronger collaboration during the development and manufacturing of clinical supplies.

“At Dunboyne, we’ll see the power of teamwork between the teams, creating a model that becomes our new way of working,” said Sanat Chattopadhyay, executive vice president and president, MSD Manufacturing Division. “This site offers the chance to harness the expertise of our exceptional manufacturing and research teams.”

Representatives from MSD meet with Leo Varadkar (center), the country’s prime minister — known as the taoiseach — and other Irish officials to celebrate the milestone.

Two facilities, one team

The two components of our Dunboyne site will play a pivotal role in our biologics pipeline. Combined, they represent our first single-use commercialization facility dedicated to manufacturing key biologics for clinical trials, product registration and launch. At the nearby manufacturing facility, teams design the process engineering necessary to produce biologics at a large scale.

The close collaboration of these teams will significantly increase our speed to market and ultimately quicken our ability to help patients.

"This integrated approach will use state-of-the-art scientific and technological innovations to get our medicines to people around the world who need them the most, faster than ever before.”

— Mike Kress

Senior vice president, chemistry, MSD Research Laboratories
Our people

Meet the scientist advancing respiratory health and inspiring women and Latino scientists

Dr. Carmen La Rosa is uncovering new ways to help people with respiratory conditions

October 3, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Growing up, Dr. Carmen La Rosa shared a room with her younger brother who struggled with asthma. She saw the impact of asthma on her brother’s ability to play and how it worried her parents when he was sick.

She also watched her mother care for her brother around the clock when he was sick. It was this experience that sparked her interest in medicine. Over the years, La Rosa was inspired by how much his condition improved with changes in therapy and a better understanding of how to manage his asthma.

 La Rosa, second from left, with her husband and children at her son’s medical school’s white coat ceremony.

La Rosa, second from left, with her husband and children at her son’s medical school’s white coat ceremony.

La Rosa’s family encouraged her interests in science and helping people. Today, she is the first woman in her family to become a doctor and is a leader in MSD’s respiratory research.

As a physician and clinical epidemiologist, La Rosa has worked in multiple therapeutic areas. But it’s through respiratory research where she’s currently bringing together her desire to help others and her professional goal to advance knowledge of lung health.

Delving into the science behind respiratory conditions

An important area of La Rosa’s research focus has been chronic cough, which is defined as a cough that lasts longer than eight weeks. Her team is exploring the physiology behind this condition to better understand it.

“I’ve seen how chronic cough can affect patients’ lives — physically, socially and emotionally — this is a story that needs to be told,” La Rosa said. “I’ve known many people who are struggling with respiratory diseases, and I want to help change that. As our research moves the field forward, I believe that there’s hope for these patients.” 

Mentoring tomorrow’s leaders

Outside of the lab, La Rosa enjoys volunteering in her community through our employee business resource group for Hispanic and Latino colleagues and speaking with Latino students about careers in science. Her goal is to inspire other women and Latinos to pursue careers in research and medicine.

When La Rosa first started her journey to become a physician-scientist, she was unaware that drug development was an option. La Rosa wants the next generation to know about the possibilities available to them in medical research and inspire them to pursue careers in science.

“Research offers you the opportunity to explore new areas in medicine, develop study designs and ultimately uncover new treatments that may help people in need,” La Rosa said. “This purpose keeps me grounded, even on the most challenging days.”

Sustainability

Diversity and inclusion strengthen everything we do

From fostering an inclusive and supportive culture to working with diverse suppliers, diversity and inclusion are integral to helping us better serve patients

September 20, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

As MSD’s chief diversity officer, Celeste Warren strives to ensure that our policies and practices provide an equal opportunity for all so that our workforce reflects the diversity of the world.

“This enables us to better understand the needs of the patients, health care providers and customers we serve,” said Warren.

And that means embedding a culture of diversity, equity and inclusion at every level of the organization, a commitment that’s central to our business growth as well as to our employees’ well-being.

While our strategic approach to building a diverse, inclusive and positive environment is part of the work we do every day, we also dedicate a full month to fostering meaningful discussions and learning. Making September Global Diversity & Inclusion (GD&I) Experience Month allows us to pause, reflect and celebrate all our important work and identify new opportunities for growth.

Prioritizing diversity and inclusion benefits employees and our business

Since our first GD&I Experience Month in 2015, we’ve made a lot of progress on our diversity and inclusion efforts in our workplace, including:

  • Strong membership growth across our 10 employee business resource groups (EBRGs), with approximately 21,500 employees who belong to EBRGs.
  • Launch of an internal Ally Resource Center to provide access to resources and educational materials to support each employee’s D&I learning journey.
  • Establishment of an internal Ally Ambassador Program to create a network of D&I leaders who provide resources, share knowledge and facilitate conversations to embed a culture of belonging, allyship for all, and psychological safety across our organization.
  • Development of an integrated disability inclusion strategy to create a disability-confident workplace culture where people with disabilities feel accepted, connected and can contribute to our purpose of using the power of leading-edge science to save and improve lives around the world.

“Building and enriching our diverse and inclusive environment involves everyone.”

  • Celeste Warren
    Vice president of global diversity and inclusion

“When every single employee embraces a welcoming mindset and can fully appreciate the experiences of others, then better discussions, decisions and outcomes will follow,” said Warren.

This approach also applies to how we do business, as we continue building momentum in a variety of priority areas, such as our work to:

  • Increase diversity in our clinical trials.
  • Ensure our marketing and commercial strategies are relevant to our diverse patients around the globe.
  • Provide opportunities to diverse suppliers in sourcing products and services.

“While we celebrate all we’ve accomplished and what makes us unique during GD&I Experience Month, we know we have more work to do,” said Warren. “We’ll continue to share best practices with other organizations, listen for new ideas, debate points of view and create environmental, cultural and business change to break down barriers and become better allies, role models, colleagues and citizens.”

Sarampión: síntomas y signos

Obtenga más información sobre qué es el virus del sarampión y cómo se propaga el sarampión

September 20, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail
Measles recolor

¿Qué es el sarampión?

El sarampión es un virus altamente contagioso que vive en la mucosidad de la nariz y la garganta de una persona infectada. Los síntomas aparecen entre 10 y 12 días después del contacto con el virus.

Los síntomas comunes del sarampión incluyen:

MSD Measles Infographic Spanish Language

Cómo se propaga el sarampión

icon
¿El sarampión se transmite por el aire?

El virus del sarampión puede vivir hasta 2 horas en un espacio aéreo donde una persona infectada tosió o estornudó

icon
¿Cuál es la tasa de transmisión del sarampión?

Si una persona tiene sarampión, hasta el 90% de las personas en riesgo cercanas a esa persona también se infectarán.

icon
¿Durante cuánto tiempo es contagioso el sarampión?

Las personas infectadas pueden contagiar el sarampión a otras personas desde 4 días antes hasta 4 días después de que aparezca el sarpullido.

icon
¿Cuánto dura el período de incubación del sarampión?

Después de estar expuesto al virus del sarampión, puede incubarse hasta por 21 días.

icon
¿El sarampión causa complicaciones?

El sarampión puede causar complicaciones de salud graves, como infecciones de oído, diarrea, neumonía y encefalitis (una inflamación del cerebro), lo que afecta la vida diaria de los pacientes y sus cuidadores (p. ej., puede provocar la pérdida de horas laborales o escolares).

El sarampión puede ser grave y provocar complicaciones.

  • El sarampión puede causar serias complicaciones de salud al afectar varios sistemas de órganos, como los oídos y los ojos (lo que conlleva a la ceguera), el tracto gastrointestinal y el sistema nervioso central, y resultar en una inflamación del cerebro y la muerte.
  • Aproximadamente el 30 porciento de los casos de sarampión notificados tienen una o más complicaciones, como encefalitis o neumonía.
  • Aproximadamente 567 personas mueren en todo el mundo por complicaciones relacionadas con el sarampión cada día, lo que equivale a 24 muertes cada hora.

Comprender los brotes de sarampión

icon

Entre 2000 y 2018, las muertes anuales notificadas por sarampión disminuyeron en un 73% a nivel mundial.

icon

El número de casos de sarampión aumentó un 659% en 2019 (874,304 casos) en comparación con 2016 (132,490 casos)

icon

Los desastres naturales y/o los conflictos pueden poner a los países en mayor riesgo de brotes mortales de sarampión al dañar la infraestructura de salud, interrumpir los servicios de salud y colocar a las personas en campamentos residenciales superpoblados.

Antes de la introducción de la vacuna contra el sarampión en 1963, el sarampión causaba aproximadamente 2,6 millones de muertes al año.

149 países reportaron 874,304 casos de sarampión a nivel mundial en 2019

Los estados miembros de la Organización Mundial de la Salud (OMS) informaron más casos de sarampión en 2019 que en cualquier año desde 1996.

En 2020, la cantidad de casos de sarampión notificados a nivel mundial fue menor, probablemente debido en parte a las regulaciones implementadas durante la pandemia de COVID-19. Sin embargo, durante el mismo año, más de 22 millones de bebés no recibieron su primera dosis de la vacuna contra el sarampión, 3 millones más que en 2019, lo que coloca a las comunidades en mayor riesgo de brotes. En 2022, la OMS y el Fondo de las Naciones Unidas para la Infancia (UNICEF) reportaron un aumento del 79% en los casos de sarampión a nivel mundial en los dos primeros meses del año en comparación con el mismo período de 2021, y alertan sobre el riesgo de enfermedades prevenibles como restricciones continuar mitigando.

El sarampión sigue siendo común en muchas partes del mundo, y los viajeros con sarampión pueden llevar la enfermedad a países que la han erradicado en gran medida. El sarampión se puede propagar rápidamente.

Health awareness

Supermodel Veronica Webb raises awareness of lung cancer screening

Pushing past her fear, Webb learned how important it is to get screened for lung cancer

September 19, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Supermodel, mother, fashion icon and blogger Veronica Webb knew that because of her former history of smoking, combined with her age, she could be at high risk for lung cancer. Yet, getting screened for cancer was something that always scared her.

Globally, while lung cancer is one of the most common types of cancers, routine screenings for the disease are less prevalent compared to screenings for other types of cancers such as cervical cancer, colorectal cancer, or breast cancer.

Low-dose CT scans are painless and not invasive

Webb faced her fears and, no stranger to cameras, documented her first lung screening to show others what she learned: low-dose CT scans are painless and not invasive.

“It’s totally painless and, one, two, three, it’s over,” Webb said. “Knowing I was cancer free gave me peace of mind. If the people in your life and the things you want to do in your life mean a lot to you, get screened.”

Select factors that increase your risk for lung cancer are:*

icon
A history of smoking
icon
Exposure to certain materials in the environment, such as radon gas, asbestos and secondhand smoke
icon
A family history of lung cancer
icon
Exposure to other materials that cause cancer like arsenic, chromium and nickel

*The above list does not include all risk factors for lung cancer

Learn more about lung cancer and the risk factors

Innovation

Macrocyclic peptides: the next wave of drug discovery

MSD scientists say the “Goldilocks” chemical modality could lead to new ways to impact disease

September 18, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Small molecules, generally taken as pills, make up nearly 90% of medicines used today. It’s hard to think of a world without them. The use of small molecules has been critical in expanding the reach of and access to medicines around the world.

But it’s challenging for small molecules to impact the large featureless surfaces of protein-protein interactions, which govern a wide range of biological processes in our bodies. To target these interactions, scientists have turned to large molecule biologic therapies, like monoclonal antibodies, which — taken by infusion or injection — have been critical in advancing the treatment of many diseases, including some cancers and autoimmune disorders.

Over a decade ago, MSD scientists began investigating a way to engineer a new type of medicine combining the ease-of-administration of a small molecule with the potency and target specificity of an antibody.

Macrocyclic peptides have shown promise in achieving this balance.

“Macrocyclic peptides allow us to cast a wider net on the protein interactions we want to drug, providing a vast and untapped opportunity to access a wider range of targets and potentially new ways to treat different diseases,” said Dani Schultz, director of chemistry, MSD Research Laboratories.

Not too big, not too small: the “Goldilocks” modality

Macrocyclic peptides have been called the “Goldilocks” chemical modality because their intermediate size combines the favorable properties of both small molecules and biologics¹. And thanks to their unique ring shape, macrocyclic peptides can cover more surface area to potentially disrupt protein-protein interactions more so than traditional, linear-shaped peptide therapies.

“The design and invention of macrocyclic peptides is notoriously complicated,” said David Thaisrivongs, director of chemistry in MSD Research Laboratories.

David Thaisrivongs

“Similarly, scaling production up for a macrocyclic peptide small molecule, with four to five times the size and complexity of a typical small molecule, represented a bold endeavor.”

  • David Thaisrivongs
    Director of chemistry, MSD Research Laboratories

For MSD, this work started by screening large libraries of cyclic peptides using messenger RNA display technology. This led to the identification of cyclic peptide leads that were optimized using 3-dimensional protein structure-based design and advanced computational techniques. Further molecular iterations and refinements improved the absorption, potency, and stability of the first candidate.

“A diverse, interdisciplinary team of skilled and determined people from across our chemistry organization has dedicated substantial efforts to advancing this science,” said Thaisrivongs.

A peptide renaissance

These macrocyclic peptide discovery efforts may one day allow us to treat diseases that have long evaded traditional small molecule approaches or improve access to medicines previously available only as an injectable.

“Macrocyclic peptides are a new modality and we’re still in the early stages of understanding their potential to impact disease and patient care,” said Schultz.

“There’s no playbook here, we’re innovating and developing new techniques on how to optimize and synthesize macrocyclic peptides — it’s really thrilling for me as a scientist because the potential is huge.”

  • Dani Schultz
    Director of chemistry, MSD Research Laboratories

Dani Schultz

[1] Beyond 20 in the 21st century: strengths, opportunities, and challenges of non-canonical amino acids in peptide drug discovery. Jennifer L. Hickey; A Dan Sindhikara; B Susan L. Zultanski  and Danielle M. Schultz

Innovation

How we’re collaborating to address antimicrobial resistance – and why we can’t do it alone

Shared commitments like the AMR Action Fund are vital to make progress against this public health threat

September 8, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

Antibiotics have transformed health care and saved countless lives. But rising levels of antimicrobial resistance (AMR) can make current antibiotics less effective. There’s no simple solution to the complex problem of AMR, but we’re committed to investing our expertise and resources alongside our partners to get antibiotics to those who need them most. Lives are at risk, and the time to act is now.

Through this groundbreaking partnership of over 20 leading pharmaceutical companies, philanthropies and organizations, we aim to bridge the gap between the innovative early antibiotic pipeline and patients. True to our legacy of preventing and treating infectious diseases, we’re proud of our commitment to invest $100 million over 10 years in the AMR Action Fund. The fund’s collective goal is to bring two to four novel antibiotics to patients and physicians by 2030.

As of early 2023, the AMR Action Fund has invested in five small biotech companies advancing research for new medicines to fight some of the most dangerous bacteria as determined by the U.S. Centers for Disease Control and Prevention and the World Health Organization.

Here are five reasons collaborative efforts are key to addressing AMR:

01.

New antibiotics are urgently needed; however, there are relatively few in development.

The future of antibiotic innovation is at serious risk. Major scientific, regulatory and economic challenges discourage innovation in antibiotics, resulting in a decline in the number of companies conducting antimicrobial R&D. Recognizing there’s no one-size-fits-all solution to the problem, our company and others have suggested a series of policy reforms across several regions of the world. However, time is running out. We need collaboration from policymakers to help antibiotic innovation flourish for decades to come.

02.

Once new antibiotics are approved, they need to be used responsibly.

At MSD, we’re making significant investments to support antimicrobial stewardship (AMS), a broad term for the implementation of evidence-based policies to slow resistance to current antimicrobials. Our investments and partnerships help hospitals around the world develop and implement patient-centered AMS programs that are customized locally based on factors like epidemiology, clinical setting and resource availability to support the responsible prescribing and use of antimicrobials. We also provide significant grant funding to support a wide range of AMS initiatives and collaborations.

Some of our global contributions to AMS include:

  • Supporting the development of several AMS Centers of Excellence throughout the world.
  • Helping public health leaders effectively monitor and address emerging AMR infections, promote AMS and customize accepted AMS strategies to meet local needs.
  • Providing significant grant-funding for numerous investigator-initiated AMS research projects.

03.

Tracking resistance trends and using data to help doctors prescribe the right medicines remains critical.

Our company has been tracking global resistance trends for over 20 years. This data helps doctors prescribe the right medicines. One of the largest and longest-running AMR surveillance programs, our Study for Monitoring Antimicrobial Resistance Trends (SMART) program has collected nearly 500,000 Gram-Negative bacterial isolates from around 220 sites in more than 60 countries since 2002.

We’re also a partner of the AMR Register, a first-ever online platform that allows pharmaceutical companies to securely share data on infection-causing pathogens with researchers, national governments and multilateral organizations working to fight AMR.

04.

AMR extends beyond human health.

The challenge of AMR is multifaceted, and a One Health approach to creating policies is critical to attain optimal health for people, animals and the environment.

When it comes to animal health, vaccines can help minimize the need for antibiotics. MSD Animal Health is one of the largest manufacturers of animal health vaccines, supplying over 102 billion doses each year.

Protecting the environment through responsible manufacturing is another key component of the One Health approach. We work with our partners in the AMR Industry Alliance to inform science-based manufacturing standards to help ensure scrutiny of industry manufacturing supply chains.

05.

The time to act against AMR is now.

With collaboration across the scientific community and policymakers, AMR is preventable.

We all have a role to play as we prepare for the next health crisis. We must act now to put measures in place to ensure we have the antibiotics we need.

“AMR is not a future problem — it’s here now, threatening human, animal and environmental health as we know it. We must take swift, collaborative action to help reduce the risk of AMR before it’s too late,” said Jennifer Zachary, executive vice president and general counsel at MSD and member of the Global Leaders Group on AMR.

Health awareness

Endometrial cancer: understanding the signs and symptoms

Learn more about how you can detect endometrial cancer

August 29, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

As we age, it’s important to recognize changes in the body. Irregular periods, postmenopausal bleeding, abnormal vaginal discharge, changes to bladder or bowel habits – these shifts can seem like a part of getting older. But for some, these changes can signal a more serious issue, as many mirror the symptoms of gynecologic cancers.

What is endometrial cancer?

In 2020, endometrial cancer was the second most commonly diagnosed gynecologic cancer worldwide. It occurs when cancerous cells form in the tissues of the endometrium or inner lining of the uterus.

How can I learn if I’m at risk for endometrial cancer?

While age, family history and lifestyle choices impact the risk of endometrial cancer, conditions that affect the body’s estrogen levels can also play a role. For example:

  • Hormone replacement therapy for menopause often includes an increase of estrogen to manage menopausal symptoms.
  • Polycystic ovarian syndrome (PCOS) usually creates higher estrogen levels and lower progesterone levels.
  • Estrogen modulators (tamoxifen) may cause the uterine lining to grow.
  • Certain comorbidities, including obesity and type 2 diabetes, have been linked as risk factors for endometrial cancer. For example, in people with obesity, fat tissue can convert certain hormones into estrogen, which increase the levels in the body.

Studies show Black women are more likely to be diagnosed with endometrial cancer than white women.

lady-and-physician-talking

What to watch out for:

  • Abnormal vaginal bleeding
  • Pelvic pain
  • Irregular menstrual cycles
  • Pain during intercourse
  • Postmenopausal bleeding
  • Abnormal vaginal discharge
  • Changes to bowel or bladder habits

How is endometrial cancer diagnosed?

If you’re experiencing any of these symptoms, talk to your doctor about getting screened. Tests to diagnose it may include:

  • Endometrial biopsy: A thin, flexible tube is inserted into the uterus to collect a tissue sample from the endometrium
  • Dilation and curettage: The cervix is dilated to collect tissue from the inner lining of the uterus.
  • Hysteroscopy: An instrument with a light and lens for viewing is inserted into the uterus to look for abnormal areas.
  • Transvaginal ultrasound: A probe is inserted into the vagina to produce images that are used to assess the pelvic organs, including the uterus.

physician and lady talking

Being diagnosed with endometrial cancer can be scary. But by speaking with your doctor, you can better understand your options and build the best path forward.

Patients

Progress in ovarian cancer research starts with patients

Reflecting on the history of clinical research and our inspiration to continue innovating for ovarian cancer patients

August 29, 2023

Share this article

.st0{fill:#00857C;}

article hero thumbnail

This article was written by Dr. Scot Ebbinghaus, VP, clinical research.

A history of groundbreaking research

More than sixty years ago, in 1958, British chemist and X-ray crystallographer Dr. Rosalind Franklin died following a two-year fight with ovarian cancer. She was only 37 years old. Her pioneering research provided the key to deciphering the structure and function of DNA — and ultimately the blueprint for life.

In 1962 her collaborators, James Watson, Francis Crick and Maurice Wilkins, were awarded the Nobel Prize for their “discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material.” Dr. Franklin’s untimely death denied her the acclaim of this prestigious scientific award (the Nobel Committee does not award the prize posthumously), but her role in this fundamental discovery has been well-documented and is now widely recognized.

Even today, advanced ovarian cancer remains one of the most difficult cancers to treat.

Dr. Franklin’s story of a life cut short by ovarian cancer remains all too common. But there remains a reason for optimism. The pace of change in cancer treatment has increased dramatically in recent years. Advances in research have given us a deeper understanding of how to target the disease, paving the way for new developments.

  • Ovarian cancer is the 8th most commonly diagnosed cancer among women in the world.
  • In 2020, globally, it’s estimated that nearly 314,000 women were diagnosed with ovarian cancer, which resulted in approximately 207,200 deaths.

Ovarian cancer more often causes signs and symptoms when the disease has spread, but can also cause nonspecific signs and symptoms in the early stages. Ovarian cancer is generally diagnosed after it has spread to other parts of the body.

The most common symptoms of ovarian cancer include:

  • Bloating.
  • Pelvic pain.
  • Trouble eating or feeling full quickly.
  • Always feeling like you have to urinate, or having to urinate often.
Women sitting at table talking

At MSD, we are focused on translating breakthrough science into oncology therapeutics. We recognize that no two patients or cancers are the same, and multiple approaches – therapeutic regimens and mechanisms of action – will be needed to outpace this disease. That’s why we have worked rigorously to expand and diversify our own internal research programs.

There is still work to be done, but we believe strongly in our potential to transform the way certain cancers are treated. And, we are constantly inspired to work harder by stories like Dr. Rosalind Franklin’s.